iMetaOmics: Advancing human and environmental health through integrated meta‐omics
iMetaOmics.,
Год журнала:
2024,
Номер
1(1)
Опубликована: Авг. 8, 2024
iMetaOmics
is
a
quarterly
international
journal
with
the
priority
of
publishing
research
work
within
scope
One
Health,
featured
well-designed
omics.
The
also
welcomes
systematic
integration
extensive
public
datasets,
new
and
meaningful
perspectives,
re-analysis
high-impact
data
yielding
different/valuable
conclusions.
microbiome
plays
critical
roles
in
human
[1],
animal
[2],
plant
nutrition
health
[3],
food
[4],
environment
[5],
as
well
other
aspects
society
(Figure
1).
Metaomics,
including
metabarcoding,
metagenomics,
metatranscriptomics,
metaproteomics,
metabolomics,
provide
unique
powerful
tools
to
better
understand
taxonomy
functions
microbiome,
biology,
[6].
Aiming
fill
gap
lacking
top
journals
field
Asia,
iMeta
Science
Society
its
thousands
Chinese
scientist
members
found
young
but
journal—iMeta
(ISSN:
2770-5986;
eISSN:
2770-596X).
It
has
published
more
than
200
high-quality
papers
since
2022,
original
articles,
reproducible
methods
protocols,
systemic
reviews
peers
updated
novel
findings,
easy-to-use
analytic
tools,
knowledge
[7].
These
publications
include
are
not
limited
gut
pertaining
diseases
[8],
microbiota
animals
(e.g.,
chicken
[9],
pig
[10],
panda
[11]),
pan-cancer
[12]
pan-genome
[13],
soil
associated
diversity
defense
[14,
15],
popular
for
metaomics
analyses
[16-18].
With
great
efforts
contributions
our
stakeholders,
like
publisher,
editorial
board
members,
authors,
reviewers,
received
first
impact
factor
23.7
2024,
gradually
accumulating
broad
diverse
audiences
readership,
especially
attracting
explosive
growth
submissions
recent
days.
To
cope
significantly
increased
submissions,
we
have
from
bimonthly
journal.
However,
publication
space
maintaining
high
standard
iMeta,
still
reject
90%
although
many
them
did
an
excellent
work.
Due
success
officially
launching
sister
(eISSN:
2996-9514,
ISSN:
2996-9506),
further
publish
articles
[19-23],
[24-28],
state-of-the-art
methodologies
[29,
30]
satisfy
increasing
submission
demand
iMeta.
Taking
advantage
same
team,
rejected
manuscripts
valuable/meaningful
findings
will
be
transferred
iMetaOmics,
together
detailed
comments
reviewers.
In
this
context,
following
review
process
shortened
promote
rapid
publishing.
Before
official
launch,
12
already
been
upon
approval
by
authors
issue.
Currently,
featuring
reanalysis
expected
that
establish
reputation
soon,
attract
wide
range
interest
readers,
contribute
progress
Human
Environmental
Health
studies.
Authors'
own
priority,
while
utilization
analysis
robust
experimental
validation
can
considered.
Multiple
evidence
required
support
conclusion.
New
strategies
advantage,
indispensable.
All
used
without
reasonable
concerns
should
publicly/temporally
accessible
reviewers
editors.
A
video
tutorial,
software
download,
installation,
operation,
result
displaying,
highly
recommended
bioinformatic
tools.
Additionally,
necessary
ethics
numbers,
clear
layouts,
figures,
significant
expected.
Chun-Lin
Shi:
Writing—original
draft;
writing—review
editing.
Tong
Chen:
Writing—review
Canhui
Lan:
Ren-You
Gan:
Jun
Yu:
Fangqing
Zhao:
Yong-Xin
Liu:
editing;
conceptualization.
Zhao
Yu
hold
position
Editor-in-Chief
iMetaOmics.
Liu,
Chen,
Lan,
Shi
Gan
Executive
Editors
Язык: Английский
Glycosylation profiling of monkeypox virus structural proteins with poly Ser-Arg materials
The Analyst,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Glycosylation
profiling
of
MPXV
structural
proteins
with
poly
SR.
Язык: Английский
Deciphering N-Glycosylation Dynamics of Serum Monoclonal Immunoglobulins in Multiple Myeloma via EThcD-sceHCD-MS/MS
Journal of Proteome Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 9, 2025
Serum
glycoprotein
glycosylation
changes
can
indicate
disease
onset
and
progression.
However,
the
site-specific
N-glycosylation
of
monoclonal
immunoglobulins
(M-proteins)
in
multiple
myeloma
(MM)
its
clinical
implications
are
unclear.
In
this
study,
we
isolated
pathogenic
micromonoclonal
IgA
or
IgG
(approximately
2
μg)
from
IgA-MM
patients
(n
=
22)
IgG-MM
30),
normal
polyclonal
healthy
controls
(HCs)
16).
Using
EThcD-sceHCD-MS/MS,
dynamics
serum
M-proteins
MM
were
determined.
Compared
with
IgA1
HCs,
had
higher
fucosylation
(58.1%
vs
32.1%,
p
<
0.001),
sialylation
(68.0%
50.8%,
0.011),
mannosylation
(1.5%
0.3%,
0.001).
While,
IgG1
(97.8%
95.3%,
addition,
specific
N-glycan
abundances
correlated
features:
for
IgA1,
HexNAc5Hex5Fuc1NeuAc1
was
associated
hypocomplementemia;
IgG1,
HexNAc4Hex3Fuc1
albumin
level
(r
-0.363,
0.049)
estimated
glomerular
filtration
rate
-0.433,
0.017);
HexNAc4Hex5
therapeutic
prognosis.
conclusion,
their
isotypes
HCs
have
distinct
profiles,
N-glycans
characteristics
Язык: Английский
Clinical glycoproteomics: methods and diseases
MedComm,
Год журнала:
2024,
Номер
5(10)
Опубликована: Окт. 1, 2024
Abstract
Glycoproteins,
representing
a
significant
proportion
of
posttranslational
products,
play
pivotal
roles
in
various
biological
processes,
such
as
signal
transduction
and
immune
response.
Abnormal
glycosylation
may
lead
to
structural
functional
changes
glycoprotein,
which
is
closely
related
the
occurrence
development
diseases.
Consequently,
exploring
protein
can
shed
light
on
mechanisms
behind
disease
manifestation
pave
way
for
innovative
diagnostic
therapeutic
strategies.
Nonetheless,
study
clinical
glycoproteomics
fraught
with
challenges
due
low
abundance
intricate
structures
glycosylation.
Recent
advancements
mass
spectrometry‐based
have
improved
our
ability
identify
abnormal
glycoproteins
samples.
In
this
review,
we
aim
provide
comprehensive
overview
foundational
principles
recent
glycoproteomic
methodologies
applications.
Furthermore,
discussed
typical
characteristics,
underlying
functions,
diseases,
brain
cardiovascular
cancers,
kidney
metabolic
Additionally,
highlighted
potential
avenues
future
glycoproteomics.
These
insights
provided
review
will
enhance
comprehension
methods
diseases
promote
elucidation
pathogenesis
discovery
novel
biomarkers
targets.
Язык: Английский
GlycoPCT: Pressure Cycling Technology-Based Quantitative Glycoproteomics Reveals Distinctive N-Glycosylation in Human Liver Biopsy Samples of Nonalcoholic Fatty Liver Disease
Journal of Proteome Research,
Год журнала:
2024,
Номер
24(1), С. 202 - 209
Опубликована: Ноя. 27, 2024
Protein
N-glycosylation
is
vital
in
the
human
liver
and
influences
functions
such
as
lipid
metabolism,
apoptosis,
inflammation.
However,
site-specific
patterns
variations
biopsy
samples
between
healthy
individuals
those
with
nonalcoholic
fatty
disease
(NAFLD)
remain
incompletely
characterized,
primarily
due
to
limitations
of
current
clinical
glycoproteomic
methods,
including
a
large
demand
for
samples,
low
efficiency
tissue
protein
extraction,
recovery
rate
intact
N-glycopeptides
(IGPs).
To
address
this
issue,
we
developed
GlycoPCT,
quantitative
method
based
on
pressure
cycling
technology.
It
enables
efficient
IGPs
accurate
analysis
trace
samples.
Our
research
revealed
total
4,459
unique
361
glycans
from
758
glycoproteins.
High-mannose
type,
complex
fucosylation
sialylation
type
N-glycans
were
significantly
upregulated
NAFLD
group
(p
<
0.001,
t
test).
Notably,
also
identified
182
67
proteins
0.05,
FC
>
1.50)
108
downregulated
44
0.67)
group.
Furthermore,
highlighted
an
essential
acute
phase
glycoprotein,
alpha-1-acid
glycoprotein
1
(A1TA),
which
synthesized
plays
significant
role
progression.
These
novel
glyco-signatures
provide
crucial
clues
diagnosis
pathogenesis
NAFLD.
Язык: Английский